Mark Bookbinder

ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.

Taavi K. Neklesa, Lawrence B. Snyder, Ryan R. Willard et al. · Journal of Clinical Oncology · 2019 · 207 citations

Medicine, Oncology, Pharmacology +16

Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models

Sheryl M. Gough, John J. Flanagan, Jessica L.F. Teh et al. · Clinical Cancer Research · 2024 · 160 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer

JJ Flanagan, Yimin Qian, SM Gough et al. · Cancer Research · 2019 · 133 citations

Medicine, Biochemistry, Endocrinology +16

Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer

Lawrence B. Snyder, John J. Flanagan, Yimin Qian et al. · Cancer Research · 2021 · 110 citations

Life Sciences, Biochemistry, Endocrinology +15

Abstract 5236: ARV-110: An androgen receptor PROTAC degrader for prostate cancer

Taavi K. Neklesa, Lawrence B. Snyder, Ryan R. Willard et al. · Cancer Research · 2018 · 62 citations

Medicine, Oncology, Pharmacology +17